Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.01) EPS for the quarter, Zacks reports.
Appili Therapeutics Stock Performance
APLIF remained flat at $0.01 during midday trading on Friday. The company’s stock had a trading volume of 1,000 shares, compared to its average volume of 9,187. Appili Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.03. The company’s 50-day moving average is $0.01 and its two-hundred day moving average is $0.01. The stock has a market capitalization of $1.20 million, a P/E ratio of -0.23 and a beta of -0.04.
About Appili Therapeutics
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Featured Stories
- Five stocks we like better than Appili Therapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
